TKI治疗慢性髓系白血病停药研究的进展  

The research progress of TKI discontinuation in chronic myeloid leukemia

作　　者：东颖[1] 赵艳红[1] 孙晶[1] 韩丽娜[1] 

机构地区：[1]哈尔滨医科大学附属第一医院血液内科,哈尔滨150001

出　　处：《中国新药杂志》2016年第7期767-770,共4页Chinese Journal of New Drugs

摘　　要：慢性髓系白血病是一种骨髓造血干细胞的恶性克隆性疾病,发病机制认为与形成BCR-ABL融合基因有关,目前伊马替尼是治疗本病的一线药物,但随着伊马替尼治疗时间延长出现耐药、不可耐受的不良反应等风险,需考虑停药问题。目前关于能否停药、何时停药、停药后能否复发等问题成为慢性髓系白血病慢性期患者关注的重点,近年来对这些问题已经完成了一些临床试验,本文将对有关伊马替尼停药方面的文献进行回顾。Chronic myeloid leukemia is a malignant hematopoietic stem cell clonal disease,and its pathogenesis is considered to be the forming of BCR-ABL fusion genes. Currently imatinib is the first-line drug to treat this disease. But the drug stopping issue has to be considered when the risk of drug resistance and intolerable adverse drug reactions emerges with progress of imatinib treatment. In recent years,whether it is necessary to stop the drug,when is the best time to stop,and whether the disease will relapse or not after stopping the drug and so on have become the focus of patients with chronic myeloid leukemia in chronic phase,and a number of clinical trials on these issues have already been completed. This article reviews the literature of imatinib discontinuation.

关 键 词：伊马替尼 停药时间 慢性髓系白血病 

分 类 号：R286.91[医药卫生—中药学]